HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain. Details of the presentations are as foll
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 HUTCHMED Limited today announces that new and updated clinical data from several ongoing studies of fruquintinib, in.